Gilead Sciences has bolstered its position in the development of next-generation cancer cell therapies with a deal to absorb Tmunity Therapeutics into its Kite unit.
Gilead Sciences' Kite Pharma unit has carved out a niche for its CD19-targeted CAR-T therapy Tecartus in acute lymphoblastic leukaemia (ALL) in Europe, free of direct competition from arch-
The FDA has approved Kite Pharma's Tecartus as a treatment for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (ALL), making CAR-T therapy an option for an
Gilead Sciences' Kite Pharma has won a key victory on appeal in its long-running dispute with Bristol Myers Squibb over patents relating to CAR-T therapies, overturning a $1.2 billion fine
Gilead Sciences' Kite Pharma has mapped out another route to the development of allogeneic or 'off-the-shelf' cell therapies for cancer, using technology developed by Appia Bio, a US startu
BioNTech has found a use for some of the windfall cash it has raked in from its COVID-19 vaccine, agreeing a deal to buy Kite Pharma's entire neoantigen T cell receptor (TCR) platform for s